$34M
Deployed across 146 projects.

We give scientists fast grants to pursue ideas that could transform longevity research but would otherwise go unfunded.
Now fundraising: AI-enabling datasetsDeployed across 146 projects.
14–25× faster than the NIH K99/R01
Well below every other funder in our comparison.
Program and current round. Three weeks describes application to decision, not funds arriving. The matching offer applies to the first $5M of new commitments; remaining availability requires confirmation. Grant goals describe the planned round, not awarded funding. Researchers receive credit for the studies, which can have several funders.
Overhead comparison. Compared with Manifund, Packard, Hewlett, Founders Pledge US and GiveWell. Administration and fundraising ÷ total expenses, from tax filings and audited accounts, FY2022–24 (Founders Pledge: 2024 only). Manifund includes an allocation estimate.
We fund work that could change the trajectory of aging research, not incremental additions to existing knowledge. Impetus focuses on work that is too speculative for government funding and too early for company formation.
We offer grants of up to $500k, with short applications and decisions within three weeks. A reviewer can champion a proposal without needing a committee’s agreement, giving unconventional ideas a route to funding.
We aim to seed ideas that grow into new research areas and paths toward treatments, and bring exceptional scientists into aging who might otherwise work elsewhere. Publications are an early sign of progress. The longer-term test is whether the work changes the field.
240+ Impetus-supported publications, from aging clocks to clinical trials.
Of round 3 grantees were new to aging research.
Of grantees were graduate students, postdocs or early-career researchers.
Of assessed papers and preprints had no NIA support identified.
34 grantees · Round 3
New to aging research. The round-three figure is 12 of 34 grantees (35.3%) marked new to longevity in the supplied classification. These flags are provisional and have not been independently reassessed. The chart describes the funded cohort; it does not establish that Impetus caused each researcher to enter aging.
84 of 134 · Rounds 1–3
Career stages. Of 134 unique grantees across rounds one to three (2021–2023), 12 were graduate students, 23 postdocs and 49 early-career researchers at their first listed award. Together, 84 of 134 is 62.7%, rounded to 63%. Some stage assignments were inferred from titles.
126 resolved assessments · FY2022–2024
NIA support assessment. Of 126 papers and preprints with resolved assessments for FY2022–2024, 75 (59.5%) had no NIA support identified for any author. Four unclear and 48 unassessed records are excluded. The assessment does not establish an absence of NIA support outside this window.
Juan Benet
Robert Rosenkranz
Hevolution Foundation
Vitalik Buterin
James Fickel
Fred Ehrsam
Michael Antonov
Jed McCaleb
Karl Pfleger
Molly Mackinlay
Feruell